GlassScriptPhysician profile
Dena S Charles
NPI 1124883848
$592.29
in general payments reported to CMS, 2019-2025
13 companies · $327 in 2025
The $327 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $265 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $592.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $131.11 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Tetraphase Pharmaceuticals, INC. | $64.20 | 2025 | |
| Baxter Healthcare | $61.99 | 2025 | Perclot |
| Takeda Pharmaceuticals U.S.A., INC. | $56.58 | 2024-2025 | Gattex |
| Acera Surgical, INC. | $55.62 | 2024-2025 | Restrata Wound Matrix |
| Thd America, INC. | $50.80 | 2024-2025 | |
| Vertex Pharmaceuticals Incorporated | $39.10 | 2024-2025 | |
| Genentech, INC. | $32.38 | 2025 | Itovebi |
| Teleflex LLC | $28.91 | 2024 | Quikclot |
| Intuitive Surgical, INC. | $22.06 | 2024 | |
| Solventum Corporation | $19.17 | 2025 | Prevena |
| Pacira Pharmaceuticals Incorporated | $16.22 | 2024 | Iovera, Exparel |
| Stryker Corporation | $14.15 | 2024 | Eikon, Spy-Phi System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dena Charles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.